We are analyzing https://link.springer.com/article/10.1007/s12149-020-01549-5.

Title:
Current status of radioligand therapy and positron-emission tomography with prostate-specific membrane antigen | Annals of Nuclear Medicine
Description:
Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein highly expressed by prostate cancer cells. PSMA-based radioligand therapy (RLT) emerged as a promising therapeutic option for prostate cancer in the early 2000s, and has been clinically validated with great enthusiasm during these past two decades. Last year, the European Association of Nuclear Medicine (EANM) published the procedure guidelines for the safe clinical practice of Lutetium-177 (177Lu)-labelled PSMA RLT. In addition, PSMA RLT with alpha-ray-emitting radioisotopes has been also developed recently. Following the clinical use of 177Lu-PSMA RLT, PSMA-targeted positron-emission tomography (PET) with Gallium-68 (68Ga) has been performed inevitably for “theranostics” for the last decade; prostate cancer is going to be treated with PSMA-RLT based on the diagnosis by PSMA-PET. Furthermore, the diagnostic usefulness of 68Ga-PSMA PET has been documented in various diseases beyond prostate cancer more recently. Regrettably, Japan is behind European countries and the United States in this field, and has just made a belated start of their clinical trials. In this review article, we briefly overviewed the current status of PSMA RLT and PSMA PET. We hope that this topic will be a particular focus of attention for most ANM readers in Japan, and that our efforts will help to facilitate the early approval of PSMA RLT and PSMA PET by the Japanese government even if only slightly.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

cancer, prostate, psma, article, rlt, gapsma, petct, imaging, patients, google, scholar, nucl, med, therapy, eur, mol, clinical, pet, cas, lupsma, acpsma, radioisotopes, study, treatment, medicine, alpharayemitting, diagnostic, japan, management, reported, nuclear, radioligand, lesions, published, early, recently, psmatargeted, radical, grade, mri, current, prostatespecific, membrane, antigen, review, access, therapeutic, prostatectomy, psa, recurrent,

Topics {✒️}

177lu-labeled low-molecular-weight agents prostate-specific membrane antigen psma-targeted positron-emission tomography 225ac-psma-617/177lu-psma-617 tandem therapy 68 ga-psma pet/ct detected manufacturing alpha-ray-emitting radioisotopes 68 ga-psma pet/ct led 68 ga-psma pet/ct scan 68ga-psma pet/ct prospectively positron-emission tomography 68ga-psma ligand pet/ct therapeutic beta-ray-emitting radioisotopes 68 ga-psma-avid primary lesions 203pb/212pb-labelled psma ligands identified 68 ga-psma-positive lesions [68ga]gallium-labelled psma ligand castration-resistant prostate cancer alpha-ray-emitting radioisotopes alpha-ray emitting radioisotopes alpha-ray-emitting radioisotope ga-pet/ct psma 68 ga-psma pet/ct 68 ga psma pet/ct ga-psma-11 pet/ct ga psma pet/ct ga-68-psma pet/ct ga-68-psma-pet/ct psma-based radioligand therapy 68ga-psma pet/ct beta-ray-emitting radioisotopes psma-targeted radiopharmaceutical therapy psma-targeted alpha therapy psma-ligand pet/ct psma-targeted radioligand therapy 177lu-labelled psma-ligands ten-fold kidney blockade psma-targeted radionuclide therapy rechallenge [177lu]lu-psma-617 article download pdf 177lu-psma radioligand therapy psma-avid benign lesions rechallenge 177lu-psma-617 rlt computational 225ac-psma rlt organ-specific disease 177lu-l1–177lu-l14 prostate disease-current status related subjects targeted alpha-therapy targeted alpha therapy hybrid pet/mri study

Questions {❓}

Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Current status of radioligand therapy and positron-emission tomography with prostate-specific membrane antigen
         description:Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein highly expressed by prostate cancer cells. PSMA-based radioligand therapy (RLT) emerged as a promising therapeutic option for prostate cancer in the early 2000s, and has been clinically validated with great enthusiasm during these past two decades. Last year, the European Association of Nuclear Medicine (EANM) published the procedure guidelines for the safe clinical practice of Lutetium-177 (177Lu)-labelled PSMA RLT. In addition, PSMA RLT with alpha-ray-emitting radioisotopes has been also developed recently. Following the clinical use of 177Lu-PSMA RLT, PSMA-targeted positron-emission tomography (PET) with Gallium-68 (68Ga) has been performed inevitably for “theranostics” for the last decade; prostate cancer is going to be treated with PSMA-RLT based on the diagnosis by PSMA-PET. Furthermore, the diagnostic usefulness of 68Ga-PSMA PET has been documented in various diseases beyond prostate cancer more recently. Regrettably, Japan is behind European countries and the United States in this field, and has just made a belated start of their clinical trials. In this review article, we briefly overviewed the current status of PSMA RLT and PSMA PET. We hope that this topic will be a particular focus of attention for most ANM readers in Japan, and that our efforts will help to facilitate the early approval of PSMA RLT and PSMA PET by the Japanese government even if only slightly.
         datePublished:2020-11-11T00:00:00Z
         dateModified:2020-11-11T00:00:00Z
         pageStart:879
         pageEnd:883
         license:http://creativecommons.org/licenses/by/4.0/
         sameAs:https://doi.org/10.1007/s12149-020-01549-5
         keywords:
            Prostate-specific membrane antigen (PSMA)
            Radioligand therapy (RLT)
            Positron-emission tomography (PET)
            Theranostics
            Radionuclides
            Nuclear Medicine
            Imaging / Radiology
         image:
         isPartOf:
            name:Annals of Nuclear Medicine
            issn:
               1864-6433
               0914-7187
            volumeNumber:34
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Singapore
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Masayuki Inubushi
               url:http://orcid.org/0000-0002-2518-7890
               affiliation:
                     name:Kawasaki Medical School
                     address:
                        name:Division of Nuclear Medicine, Department of Radiology, Kawasaki Medical School, Kurashiki, Japan
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Hiroyuki Miura
               affiliation:
                     name:Hirosaki University School of Medicine
                     address:
                        name:Department of Radiology, Hirosaki University School of Medicine, Hirosaki, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ichiei Kuji
               affiliation:
                     name:Saitama Medical University International Medical Center
                     address:
                        name:Department of Nuclear Medicine, Saitama Medical University International Medical Center, Hidaka, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kimiteru Ito
               affiliation:
                     name:National Cancer Center Hospital
                     address:
                        name:Department of Diagnostic Radiology, National Cancer Center Hospital, Chuo-ku, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ryogo Minamimoto
               affiliation:
                     name:National Center for Global Health and Medicine
                     address:
                        name:Division of Nuclear Medicine, Department of Radiology, National Center for Global Health and Medicine, Shinjyuku-ku, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Current status of radioligand therapy and positron-emission tomography with prostate-specific membrane antigen
      description:Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein highly expressed by prostate cancer cells. PSMA-based radioligand therapy (RLT) emerged as a promising therapeutic option for prostate cancer in the early 2000s, and has been clinically validated with great enthusiasm during these past two decades. Last year, the European Association of Nuclear Medicine (EANM) published the procedure guidelines for the safe clinical practice of Lutetium-177 (177Lu)-labelled PSMA RLT. In addition, PSMA RLT with alpha-ray-emitting radioisotopes has been also developed recently. Following the clinical use of 177Lu-PSMA RLT, PSMA-targeted positron-emission tomography (PET) with Gallium-68 (68Ga) has been performed inevitably for “theranostics” for the last decade; prostate cancer is going to be treated with PSMA-RLT based on the diagnosis by PSMA-PET. Furthermore, the diagnostic usefulness of 68Ga-PSMA PET has been documented in various diseases beyond prostate cancer more recently. Regrettably, Japan is behind European countries and the United States in this field, and has just made a belated start of their clinical trials. In this review article, we briefly overviewed the current status of PSMA RLT and PSMA PET. We hope that this topic will be a particular focus of attention for most ANM readers in Japan, and that our efforts will help to facilitate the early approval of PSMA RLT and PSMA PET by the Japanese government even if only slightly.
      datePublished:2020-11-11T00:00:00Z
      dateModified:2020-11-11T00:00:00Z
      pageStart:879
      pageEnd:883
      license:http://creativecommons.org/licenses/by/4.0/
      sameAs:https://doi.org/10.1007/s12149-020-01549-5
      keywords:
         Prostate-specific membrane antigen (PSMA)
         Radioligand therapy (RLT)
         Positron-emission tomography (PET)
         Theranostics
         Radionuclides
         Nuclear Medicine
         Imaging / Radiology
      image:
      isPartOf:
         name:Annals of Nuclear Medicine
         issn:
            1864-6433
            0914-7187
         volumeNumber:34
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Singapore
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Masayuki Inubushi
            url:http://orcid.org/0000-0002-2518-7890
            affiliation:
                  name:Kawasaki Medical School
                  address:
                     name:Division of Nuclear Medicine, Department of Radiology, Kawasaki Medical School, Kurashiki, Japan
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Hiroyuki Miura
            affiliation:
                  name:Hirosaki University School of Medicine
                  address:
                     name:Department of Radiology, Hirosaki University School of Medicine, Hirosaki, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ichiei Kuji
            affiliation:
                  name:Saitama Medical University International Medical Center
                  address:
                     name:Department of Nuclear Medicine, Saitama Medical University International Medical Center, Hidaka, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kimiteru Ito
            affiliation:
                  name:National Cancer Center Hospital
                  address:
                     name:Department of Diagnostic Radiology, National Cancer Center Hospital, Chuo-ku, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ryogo Minamimoto
            affiliation:
                  name:National Center for Global Health and Medicine
                  address:
                     name:Division of Nuclear Medicine, Department of Radiology, National Center for Global Health and Medicine, Shinjyuku-ku, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Annals of Nuclear Medicine
      issn:
         1864-6433
         0914-7187
      volumeNumber:34
Organization:
      name:Springer Singapore
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Kawasaki Medical School
      address:
         name:Division of Nuclear Medicine, Department of Radiology, Kawasaki Medical School, Kurashiki, Japan
         type:PostalAddress
      name:Hirosaki University School of Medicine
      address:
         name:Department of Radiology, Hirosaki University School of Medicine, Hirosaki, Japan
         type:PostalAddress
      name:Saitama Medical University International Medical Center
      address:
         name:Department of Nuclear Medicine, Saitama Medical University International Medical Center, Hidaka, Japan
         type:PostalAddress
      name:National Cancer Center Hospital
      address:
         name:Department of Diagnostic Radiology, National Cancer Center Hospital, Chuo-ku, Japan
         type:PostalAddress
      name:National Center for Global Health and Medicine
      address:
         name:Division of Nuclear Medicine, Department of Radiology, National Center for Global Health and Medicine, Shinjyuku-ku, Japan
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Masayuki Inubushi
      url:http://orcid.org/0000-0002-2518-7890
      affiliation:
            name:Kawasaki Medical School
            address:
               name:Division of Nuclear Medicine, Department of Radiology, Kawasaki Medical School, Kurashiki, Japan
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Hiroyuki Miura
      affiliation:
            name:Hirosaki University School of Medicine
            address:
               name:Department of Radiology, Hirosaki University School of Medicine, Hirosaki, Japan
               type:PostalAddress
            type:Organization
      name:Ichiei Kuji
      affiliation:
            name:Saitama Medical University International Medical Center
            address:
               name:Department of Nuclear Medicine, Saitama Medical University International Medical Center, Hidaka, Japan
               type:PostalAddress
            type:Organization
      name:Kimiteru Ito
      affiliation:
            name:National Cancer Center Hospital
            address:
               name:Department of Diagnostic Radiology, National Cancer Center Hospital, Chuo-ku, Japan
               type:PostalAddress
            type:Organization
      name:Ryogo Minamimoto
      affiliation:
            name:National Center for Global Health and Medicine
            address:
               name:Division of Nuclear Medicine, Department of Radiology, National Center for Global Health and Medicine, Shinjyuku-ku, Japan
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Division of Nuclear Medicine, Department of Radiology, Kawasaki Medical School, Kurashiki, Japan
      name:Department of Radiology, Hirosaki University School of Medicine, Hirosaki, Japan
      name:Department of Nuclear Medicine, Saitama Medical University International Medical Center, Hidaka, Japan
      name:Department of Diagnostic Radiology, National Cancer Center Hospital, Chuo-ku, Japan
      name:Division of Nuclear Medicine, Department of Radiology, National Center for Global Health and Medicine, Shinjyuku-ku, Japan

External Links {🔗}(70)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Isotope
Prism.js

CDN Services {📦}

Crossref

3.99s.

LINK . SPRINGER . COM {}